Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03283371
Brief Title: Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy (OPUS)

First Submitted : September 12, 2017
First Submitted that Met QC Criteria : September 12, 2017
First Posted : September 14, 2017

Results First Submitted : December 24, 2020
Results First Submitted that Met QC Criteria : April 26, 2021
Results First Posted : April 27, 2021

Last Update Submitted that Met QC Criteria : April 26, 2021
Last Update Posted : April 27, 2021